According to the report, the molecular diagnostics market is anticipated to grow from USD 16.5 Billion in 2024 to USD 33.2 Billion in 2035 at a CAGR of 6.6% during the forecast period. The molecular diagnostics market continues to expand rapidly as more patients desire to possess affordable and precise methods of early disease detection. These diagnostic tests aid in the identification of a variety of conditions including cancers, infectious diseases and genetic conditions with amazing precision, and often before any symptoms are present. These tests are vital to everyday clinical practice in hospitals, and are expected to become an equally important set of tools for use in the home. As awareness grows about the dependability and context of these tests, patients and healthcare stakeholders are using them with greater standardization and acceptance across the globe.
Many of the recently launched advanced molecular diagnostic kits and devices are cutting-edge - and have been developed for speed (results less than a few hours - real-time) - and some are home diagnostics or created for "climate remote" clinics. Many kits include a connection to health applications, which tracks outcomes of tests with alerts and the ability for real-time sharing of summary data with a physician. These smart features will allow for care planning and early intervention, and will support patients in attuning themselves to their health with more options, flexibility, and behavioral engagement.
The federal and provincial governments and public health agencies are also investing in the molecular diagnostics market through screening programs and reformulating health promotion guidelines to support molecular testing. This builds relationships of trust with the public, while expanding health promotion and disease prevention interventions that support personalized and technological-driven healthcare. The demand for more personal amplification of more personal space through personal empowerment and accessible technology. As the demand for smarter, efficient, personalized and eco-conscious healthcare options grows, molecular diagnostics are becoming critical to making ambient medicine optimal for contemporary multiple-level health access.
The molecular diagnostics market is dominated by a handful of large, global healthcare and biotechnology companies such as Roche, Thermo Fischer Scientific, Abbott, and Danaher - companies that have the research capability, a worldwide supply distribution network with an array of on-platform technologies and methodologies for testing. And these companies have established their own platforms and commitment to advancing testing technologies and methodologies (e.g, real-time PCR, next generation sequencing and point-of-care testing), which gives them a front-row seat in identifying opportunities related to disease early detection, personalized medicine and pandemic response.
The supply side of molecular diagnostics has not come without its complexities. High testing costs, absence of infrastructure in low-income regions, and a limited capacity of trained personnel can limit access to molecular diagnostics. In addition, the nature of some of the regulatory approvals surrounding complex product development and commercialization of products can hinder access to molecular diagnostics, as navigating regulatory approvals can be complicated and slow the launch of these products. Many tests require rigorous laboratory development and complex equipment, which can limit access for people living in remote or rural areas. Growing barriers that restrict availability and affordability can occur, but especially where health systems are new, limited, or overcrowded.
Moreover, the outlook is optimistic for the molecular diagnostics market. Growing awareness for early disease detection, a growing pool of advocates for personalized treatment options, and increased urgency as a result of infectious disease, like COVID-19, are favorable trends for the growth of the market. The industry is leveraging lean technologies as AI incorporation in labs, point-of-care molecular diagnostic testing, and digital health entries are enhancing the speed and accessibility to diagnostics.
Tariff regulations, which differ from country to country, can influence the molecular diagnostics market significantly. High import duty on key diagnostic materials such as testing kits and reagents, and advanced laboratory equipment raise the overall costs of molecular tests in particular, especially in low and lower middle-income countries. This raises the barriers to high-quality diagnostic services and the uptake of newer technology such as next-generation sequencing and CRISPR-based testing is slower.
Additionally, tariffs create uncertainty not only in their trade policy, but also regulatory and approval lack of consistency between borders and delays in the movement of components for developing new tests or manufacturing. For businesses, the result is often institutions operating in higher (professional) production costs, unpredictable cost because of the way their supply chain is managed, and restricted communities outside their own for subsequent commercial growth. Tariffs present considerable pressure on smaller diagnostic startups who are facing these trade barriers. Ultimately, tariffs can reduce patient affordability, delay innovation and enhance health inequity across terms of countries with stronger local production and those relying on imports to meet their diagnostic needs.
Key players operating in the molecular diagnostics market include Abbott Laboratories, Agilent Technologies, Inc., Becton, Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories, Inc., Danaher Corporation (Cepheid), Exact Sciences Corporation, Foundation Medicine, Inc., Fulgent Genetics, GenMark Diagnostics (Roche subsidiary), Grifols, S.A., Hologic, Inc., Illumina, Inc., Luminex Corporation, Myriad Genetics, Natera, Inc., Oxford Nanopore Technologies, PerkinElmer, Inc., Qiagen N.V., Roche Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific Inc., Twist Bioscience, and Other Key Players.
MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.
We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.
800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.
+1(302)303-2617
info@marketgenics.co
3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.
sales@marketgenics.co
Table of Contents
Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography
We will customise the research for you, in case the report listed above does not meet your requirements.
Get 10% Free Customisation